Literature DB >> 20421572

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Chris H Polman1, Richard A Rudick.   

Abstract

BACKGROUND: The Multiple Sclerosis Functional Composite (MSFC) provides a focused and sensitive evaluation of disability in patients with multiple sclerosis (MS) that may be more responsive to change than that provided by the Expanded Disability Status Scale. EXPERT CLINICAL OPINION: The MSFC is a 3-part quantitative instrument that measures arm, leg, and cognitive function with the 9-Hole Peg Test (arm/hand dexterity), the Timed 25-Foot Walk (leg function), and the Paced Auditory Serial Addition Test (3-second version, PASAT3; cognition). The MSFC has excellent test-retest reliability. Construct validity was supported by expected differences in scores between patients with primary or secondary progressive MS compared with relapsing-remitting MS. Concurrent validity was demonstrated by significant correlations with the Expanded Disability Status Scale, the Sickness Impact Profile, and the Short Form-36, particularly on the physical components of the latter 2 scales. MSFC scores also correlate with MRI changes. Limitations of the MSFC include practice effects with the PASAT and to a lesser extent the 9-Hole Peg Test, variations in the reference populations used to calculate Z-scores, and the lack of an accepted definition of a clinically meaningful change. FUTURE DIRECTIONS: Future research should be directed at adding a test that measures visual function (e.g., contrast acuity), at replacing the PASAT by a cognition test that has better measurement characteristics, and at developing methods to better understand the clinical relevance of changes in MSFC scores.

Entities:  

Mesh:

Year:  2010        PMID: 20421572     DOI: 10.1212/WNL.0b013e3181dbb571

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  52 in total

1.  Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Authors:  Núria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Delon La Puma; Francesc Graus; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

2.  Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.

Authors:  Céline Louapre; Vincent Perlbarg; Daniel García-Lorenzo; Marika Urbanski; Habib Benali; Rana Assouad; Damien Galanaud; Léorah Freeman; Benedetta Bodini; Caroline Papeix; Ayman Tourbah; Catherine Lubetzki; Stéphane Lehéricy; Bruno Stankoff
Journal:  Hum Brain Mapp       Date:  2014-03-31       Impact factor: 5.038

3.  Longitudinal relationships among posturography and gait measures in multiple sclerosis.

Authors:  Nora E Fritz; Scott D Newsome; Ani Eloyan; Rhul Evans R Marasigan; Peter A Calabresi; Kathleen M Zackowski
Journal:  Neurology       Date:  2015-04-15       Impact factor: 9.910

4.  Impairments in Walking Ability, Dexterity, and Cognitive Function in Multiple Sclerosis Are Associated with Different Regional Cerebellar Gray Matter Loss.

Authors:  Matthias Grothe; Martin Lotze; Sönke Langner; Alexander Dressel
Journal:  Cerebellum       Date:  2017-12       Impact factor: 3.847

5.  Distinguishing among multiple sclerosis fallers, near-fallers and non-fallers.

Authors:  Nora E Fritz; Ani Eloyan; Moira Baynes; Scott D Newsome; Peter A Calabresi; Kathleen M Zackowski
Journal:  Mult Scler Relat Disord       Date:  2017-11-22       Impact factor: 4.339

6.  A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.

Authors:  Douglas D Gunzler; Nathan Morris
Journal:  Stat Med       Date:  2015-06-04       Impact factor: 2.373

7.  Step-length variability in minimally disabled women with multiple sclerosis or clinically isolated syndrome.

Authors:  Melanie Flegel; Katherine Knox; Darren Nickel
Journal:  Int J MS Care       Date:  2012

8.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

9.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

Review 10.  New approaches in the management of multiple sclerosis.

Authors:  Laurie J Barten; Douglas R Allington; Kendra A Procacci; Michael P Rivey
Journal:  Drug Des Devel Ther       Date:  2010-11-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.